CNS Disorders  >>  elenbecestat (E2609)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
elenbecestat (E2609) / Eisai, Biogen
MissionAD1, NCT02956486 / 2016-003928-23: A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease

Not Appicable Apr 2021 - Jun 2021 : From MISSION AD1 trial in Alzheimer's disease (trial terminated)
Not Appicable Mar 2019 - Mar 2019 : Enrollment completion of P3 MISSION AD1 and MISSION AD2 trials (trial terminated)
Terminated
3
2212
Europe, Canada, Japan, US, RoW
Elenbecestat, E2609, Placebo
Eisai Co., Ltd., Biogen
Alzheimer's Disease
01/20
01/20
MissionAD2, NCT03036280 / 2016-004128-42: A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_

Not Appicable Apr 2021 - Jun 2021 : From MISSION AD2 trial in Alzheimer's disease (trial terminated)
Not Appicable Mar 2019 - Mar 2019 : Enrollment completion of P3 MISSION AD1 and MISSION AD2 trials (trial terminated)
Active, not recruiting
3
1018
Europe, Canada, Japan, US, RoW
Elenbecestat (E2609), Elenbecestat, Placebo
Eisai Co., Ltd., Biogen
Alzheimer's Disease
11/23
11/23

Download Options